MX2021010875A - Composiciones de éster de ácido cannabinoide y sus usos. - Google Patents
Composiciones de éster de ácido cannabinoide y sus usos.Info
- Publication number
- MX2021010875A MX2021010875A MX2021010875A MX2021010875A MX2021010875A MX 2021010875 A MX2021010875 A MX 2021010875A MX 2021010875 A MX2021010875 A MX 2021010875A MX 2021010875 A MX2021010875 A MX 2021010875A MX 2021010875 A MX2021010875 A MX 2021010875A
- Authority
- MX
- Mexico
- Prior art keywords
- acid ester
- cannabinoid
- cannabinoid acid
- ester compositions
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
La presente descripcion proporciona composiciones farmaceuticas que incluyen un compuesto de ester de acido cannabinoide solo o en combinacion con uno o mas compuestos cannabinoides adicionales. En algunas modalidades, el compuesto de ester de acido cannabinoide es un ester de acido cannabidiolico. Tambien se proporciona una variedad de 5 aplicaciones terapeuticas en las que son útiles los compuestos de ester de acido cannabinoide y las composiciones farmaceuticas, que incluyen las terapias de combinacion que usan compuestos de ester de acido cannabinoide y uno o mas agentes terapeuticos adicionales.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962816935P | 2019-03-12 | 2019-03-12 | |
US201962820302P | 2019-03-19 | 2019-03-19 | |
US201962827873P | 2019-04-02 | 2019-04-02 | |
US201962856160P | 2019-06-03 | 2019-06-03 | |
US201962869568P | 2019-07-02 | 2019-07-02 | |
US201962903848P | 2019-09-22 | 2019-09-22 | |
US201962903849P | 2019-09-22 | 2019-09-22 | |
US201962903852P | 2019-09-22 | 2019-09-22 | |
PCT/US2020/022298 WO2020186010A1 (en) | 2019-03-12 | 2020-03-12 | Cannabinoid acid ester compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010875A true MX2021010875A (es) | 2021-12-10 |
Family
ID=70155387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010875A MX2021010875A (es) | 2019-03-12 | 2020-03-12 | Composiciones de éster de ácido cannabinoide y sus usos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220151972A1 (es) |
EP (1) | EP3937925A1 (es) |
JP (1) | JP2022524780A (es) |
KR (1) | KR20210151816A (es) |
CN (1) | CN113840598A (es) |
AU (1) | AU2020235617A1 (es) |
CA (1) | CA3132637A1 (es) |
MX (1) | MX2021010875A (es) |
WO (1) | WO2020186010A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4103173A4 (en) * | 2020-05-25 | 2024-02-28 | Innocan Pharma Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASIS OF THE SCALP |
CA3192827A1 (en) * | 2020-11-05 | 2022-05-12 | Denis Marcel Barron | Substituted resorcylic acid compounds as ampk activator and uses thereof |
CA3198547A1 (en) * | 2020-11-16 | 2022-05-19 | Mark RIDALL | Rapidly infusing platform and compositions for therapeutic treatment in humans |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
GR1010219B (el) | 2021-01-22 | 2022-04-08 | Ekati Alchemy Lab Sl, | Φαρμακευτικα προϊοντα βασισμενα σε εστερες κανναβινοειδων οξεων |
JP2024514362A (ja) * | 2021-04-22 | 2024-04-01 | パイク セラピューティクス インコーポレイテッド | 慢性疼痛の処置のための経皮医薬製剤 |
EP4370106A1 (en) * | 2021-07-13 | 2024-05-22 | EPM (IP), Inc. | Cannabidiolic acid esters for treating prader-willi syndrome |
KR20230039979A (ko) * | 2021-09-15 | 2023-03-22 | 서울대학교산학협력단 | 아토피 피부염 예방 또는 치료용 겔 조성물 |
DE102022128474A1 (de) | 2021-10-27 | 2023-04-27 | fibi UG (haftungsbeschränkt) | Zusammensetzung umfassend Copaibaextrakt und Magnesiumsalz insbesondere zur Verbesserung des körperlichen Wohlbefindens bei Menstruationsbeschwerden oder bei allgemeinen Verspannungszuständen |
CN116983264B (zh) * | 2023-09-28 | 2023-12-22 | 中国农业科学院农产品加工研究所 | 一种二氢大麻二酚二苯甲酸酯的包埋体系及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
DE102009019322A1 (de) * | 2009-04-30 | 2010-11-11 | The Health Concept Gmbh | Verfahren zur Herstellung von Synthetischen Cannabinoiden |
WO2011117429A1 (es) * | 2010-03-26 | 2011-09-29 | Vivacell Biotechnology España, S.L | Derivados quinona de cannabinoides |
WO2014182655A1 (en) | 2013-05-06 | 2014-11-13 | Stiefel Laboratories, Inc. | Assay for screening a compound for the ability to modulate proinflammatory cytokine production in human skin |
AU2016367543A1 (en) * | 2015-12-07 | 2018-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Compositions of therapeutic substances, methods and uses thereof |
LT6486B (lt) * | 2016-04-13 | 2018-01-10 | UAB "SatiMed" | Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui |
AU2018287018B2 (en) * | 2017-06-20 | 2022-04-28 | University Of Guelph | Cannabidiolic acid esters compositions and uses thereof |
FR3071508B1 (fr) | 2017-09-26 | 2022-07-29 | Genoskin | Modele ex vivo de peau humaine inflammee et ses utilisations pour le criblage de composes anti-inflammatoires |
-
2020
- 2020-03-12 MX MX2021010875A patent/MX2021010875A/es unknown
- 2020-03-12 KR KR1020217032530A patent/KR20210151816A/ko unknown
- 2020-03-12 CN CN202080034838.6A patent/CN113840598A/zh active Pending
- 2020-03-12 JP JP2021553383A patent/JP2022524780A/ja active Pending
- 2020-03-12 EP EP20716667.9A patent/EP3937925A1/en active Pending
- 2020-03-12 US US17/437,780 patent/US20220151972A1/en active Pending
- 2020-03-12 AU AU2020235617A patent/AU2020235617A1/en active Pending
- 2020-03-12 WO PCT/US2020/022298 patent/WO2020186010A1/en unknown
- 2020-03-12 CA CA3132637A patent/CA3132637A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020186010A1 (en) | 2020-09-17 |
EP3937925A1 (en) | 2022-01-19 |
KR20210151816A (ko) | 2021-12-14 |
JP2022524780A (ja) | 2022-05-10 |
CA3132637A1 (en) | 2020-09-17 |
US20220151972A1 (en) | 2022-05-19 |
AU2020235617A1 (en) | 2021-11-04 |
CN113840598A (zh) | 2021-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010875A (es) | Composiciones de éster de ácido cannabinoide y sus usos. | |
MX2022000711A (es) | Inhibidores de parp1. | |
MX2022002183A (es) | Composiciones de éster de ácido cannabinoide y sus usos. | |
GEP20237506B (en) | Pcsk9 antagonist compounds | |
EA200970791A1 (ru) | N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ | |
MX2020013853A (es) | Compuestos innovadores. | |
GEP20207147B (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
GEP201706783B (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
BR112015013123A2 (pt) | inibidores de beta-lactamase | |
ECSP077299A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
UY33397A (es) | Forma sólida de un naftaleno carboxamida | |
MY165124A (en) | Semifluorinated alkane compositions | |
BR112019024785A2 (pt) | composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
PH12018500377A1 (en) | Novel annelated benzamides | |
EP3995489A3 (en) | Disulfide compounds for delivery of pharmaceutical agents | |
SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
MX2020007403A (es) | Compuestos de tetrahidroisoquinolina. | |
JOP20220006A1 (ar) | مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا | |
TN2019000156A1 (en) | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease |